Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.98 EUR
Change Today 0.00 / 0.00%
Volume 16.5K
MKEA On Other Exchanges
EN Paris
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

mauna kea technologies (MKEA) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/4/14 - €9.77
52 Week Low
07/3/15 - €3.93
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

mauna kea technologies (MKEA) Related Businessweek News

No Related Businessweek News Found

mauna kea technologies (MKEA) Details

Mauna Kea Technologies S.A. engages in the design, development, and manufacture of medical devices for medical imaging. The company offers Cellvizio, a probe-based Confocal Laser Endomicroscopy solution that performs microscopic imaging. Its Cellvizio platform provides various Confocal Miniprobes to answer the specific needs of each endoscopy field comprising GastroFlex for Eso-Gastro-Duodenoscopy; CholangioFlex for Confocal Cholangioscopy in ERCP; ColoFlex for Colonoscopy; and AlveoFlex for Bronchoscopy and Alveoscopy. The company is also involved in the development of pre-clinical research systems, including ProFlex microprobes; Laser Scanning Unit, a high-resolution fibered confocal microscope; and ImageCell software that quantifies data in real time for various applications, such as deep brain imaging, Angiogenesis, peripheral nervous system, GI cancer research, stem cells, and pancreatic cancer imaging. It primarily serves the gastroenterologists and pulmonologists. The company was founded in 2000 and is based in Paris, France.

120 Employees
Last Reported Date: 04/14/15
Founded in 2000

mauna kea technologies (MKEA) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: €205.0K
Compensation as of Fiscal Year 2014.

mauna kea technologies (MKEA) Key Developments

Mauna Kea Technologies SAS Presents at French Life Science Days conference, Jun-17-2015

Mauna Kea Technologies SAS Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Mauna Kea Technologies Announces CE Mark for Use of Cellvizio During Interventional Radiology Procedures

Mauna Kea Technologies announced that CE mark for the use of Cellvizio in interventional radiology indications. This new regulatory milestone positions Cellvizio as a unique adjunct to important therapeutic procedures that are in great need for direct and real-time image-guidance. Cellvizio brings real-time visualization of tissue at the microscopic level, representing a major advance in image-guided interventions. In this setting, the AQ-Flex 19 IR Cellvizio probe can be delivered through a standard percutaneous needle and provide microscopic images of lesions within solid organs such as the liver, kidney, or lung. Access to Cellvizio imaging during the procedure may provide a wide range of benefits to patients such as real-time assessment of needle-placement before focal therapeutic interventions and evaluation of completeness of tumor ablation.

Mauna Kea Technologies Announces CE Mark for Use of Cellvizio in Minimally Invasive Surgery

Mauna Kea Technologies announced CE mark for the use of Cellvizio in minimally invasive laparoscopic surgical indications. This regulatory milestone positions Cellvizio for useful imaging support in a wide range of oncologic surgical procedures, many of which have already been investigated successfully in several clinical studies throughout Europe. Cellvizio brings real-time visualization of tissue at the microscopic level, representing a major advance in image-guided surgery. In this setting, the Celioflex Cellvizio probe can be delivered laparoscopically through a trocar and manipulated in the surgical field with standard laparoscopic hand-held instruments. Usage of the Cellvizio probe with robotic instruments will be accessible in the near future. Access to real-time visualization of tissue may provide a range of benefits to surgeons and patients such as improved frozen section sampling, more accurate tumor margin detection and improved surgical planning. In addition, Cellvizio is compatible and synergistic with macroscopic optical fluorescent imaging systems currently used in a range of surgical applications.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKEA:FP €3.98 EUR 0.00

MKEA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.55 USD 0.00
Guided Therapeutics Inc $0.11 USD +0.004
MELA Sciences Inc $1.16 USD +0.01
Optiscan Imaging Ltd A$0.05 AUD -0.005
Verisante Technology Inc C$0.12 CAD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation MKEA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAUNA KEA TECHNOLOGIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at